Early Stage Clinical

Since September 19, 2016, QPS has closely collaborated with G-CURE, a cardiovascular research organization originating from and closely linked to the Department of Cardiology at the University Medical Center Groningen (UMCG) in the Netherlands. Now, three years later, QPS and G-CURE are transforming their relationship into a partnership, establishing an internationally competitive cardiovascular drug development infrastructure. By […]

Newark, Delaware, April 22, 2019 – QPS, a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services, today announced its successful implementation of ClinSpark, an eSource technology platform for Phase I automation, to support double digit growth in Phase I clinical trials. According to Grandview Research, the global clinical trials market

Newark, Delaware, March 25, 2019 – With Brexit pending and the European Medicines Agency (EMA) headquarters moving from London to the Netherlands, QPS, a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services, today announced it is ready to take on clinical trials that need to relocate and is prepared to

QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, today announced the expansion of its U.S.-based Phase I clinical trial capabilities to support the growing needs of its pharmaceutical, biotechnology and CRO partners. To fill their drug pipelines, large pharmaceutical and biotechnology companies are buying promising drug compounds that have

Study to be conducted at QPS facilities in Groningen, the Netherlands Kancera AB, a pharmaceutical development company currently focused on the treatment of cancer and autoimmune disease, today announced that it has selected QPS as the CRO (Contract Research Organization) to manage the first-in-human study with its drug candidate KAND567. The first-in-human study with KAND567

The first-in-human study with ACT017 will be conducted at QPS facilities in Groningen, the Netherlands. Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it selected its CRO (Contract Research Organization) to manage its clinical study phase I. The first-in-human study with ACT017 will be conducted at QPS